R. Schnitzer

发表

Drugging an undruggable pocket on KRAS

M. Koegl, S. Fesik, A. Waterson, 2019, Proceedings of the National Academy of Sciences.

A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity.

C. Stratowa, T. Metz, A. Baum, 1999, Anti-cancer drug design.

Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance

P. Ettmayer, S. Carotta, M. Kerenyi, 2020, Molecular Cancer Therapeutics.

Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling

Markus J. Bauer, Julian E. Fuchs, J. Zuber, 2022, Nature Cancer.

Reply to Tran et al.: Dimeric KRAS protein–protein interaction stabilizers

M. Koegl, S. Fesik, A. Waterson, 2020, Proceedings of the National Academy of Sciences.

Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.

Markus J. Bauer, P. Ettmayer, D. Rudolph, 2016, Journal of medicinal chemistry.

Hit and Lead Generation Strategies

R. Schnitzer, P. Ettmayer, A. Bergner, 2017 .

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

William Farnaby, Peter Greb, Michael Galant, 2019, Nature Chemical Biology.

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.

M. Koegl, P. Ettmayer, T. Voss, 2017, Cell reports.

Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor BI-4924 Disrupts Serine Biosynthesis.

P. Ettmayer, W. Sommergruber, M. Pearson, 2019, Journal of medicinal chemistry.

Start selective and rigidify: The discovery path towards a next generation of EGFR tyrosine kinase inhibitors.

Julian E. Fuchs, P. Ettmayer, A. Baum, 2019, Journal of medicinal chemistry.

Chemically Induced Degra dation of the Oncogenic Transcription Factor BCL 6 Graphical Abstract Highlights

M. Koegl, P. Ettmayer, T. Voss, 2022 .

One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.

P. Ettmayer, N. Kraut, M. Gmachl, 2021, Journal of medicinal chemistry.

The use of genetically engineered cells in drug discovery.

G Loeber, R Schnitzer, R. Schnitzer, 1998, Genetic engineering.

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

M. Koegl, T. Owen-Hughes, P. Ettmayer, 2019 .

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

M. Koegl, T. Owen-Hughes, P. Ettmayer, 2019 .